Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus TP as neoadjuvant therapy for local advanced cervical carcinoma
NCT05013268Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in cervical squamous cell carcinoma (CSCC), sponsored by Ruijin Hospital. Primary endpoint: Major Pathological Response Rate at 8 weeks. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT05013268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013268.